FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200894866> ?p ?o ?g. }

• W3200894866 abstract "Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high mortality, and there are no uniform guidelines for the treatment of this disease. Anti-CD19 chimeric antigen receptor (CAR) T cells show significant efficacy in treatment of relapse/refractory diffuse large B-cell lymphoma (DLBCL). Treatment using anti-CD19-CAR T-cell therapy in PTLD has been limited by immunosuppressants and has not been widely employed. In this study, a refractory post kidney transplant DLBCL patient with a high tumor burden was enrolled in a clinical trial of anti-CD19-CAR T-cell therapy. The tacrolimus dose was not decreased during combination chemotherapy, as the creatinine level of the patient increased. To improve the function of autologous T cells, combination therapy with anti-CD19-CAR T cells and programmed cell death 1 (PD-1) inhibitors was selected. After treatment with the combination therapy, the patient was diagnosed with grade 1 cytokine release syndrome and grade 3 immune effector cell-associated neurotoxicity syndrome. The amplification peak of anti-CD19-CAR T cells reached 9.01% on day 7. With PD-1 inhibitor maintenance therapy, his disease was maintained in partial remission for 18 weeks. However, his tumor suddenly increased in size, and he discontinued the treatment, including radiation therapy. The anti-CD19-CAR T cell and PD-1 inhibitors have a combined effect on PTLD, and this combination therapy needs to be further explored." @default.
• W3200894866 created "2021-09-27" @default.
• W3200894866 creator A5023940382 @default.
• W3200894866 creator A5049385418 @default.
• W3200894866 creator A5053780153 @default.
• W3200894866 creator A5061270653 @default.
• W3200894866 creator A5061406271 @default.
• W3200894866 creator A5070406189 @default.
• W3200894866 creator A5089086011 @default.
• W3200894866 date "2021-09-16" @default.
• W3200894866 modified "2023-10-10" @default.
• W3200894866 title "Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review" @default.
• W3200894866 cites W1964106115 @default.
• W3200894866 cites W1967587135 @default.
• W3200894866 cites W1989488484 @default.
• W3200894866 cites W1994080024 @default.
• W3200894866 cites W2055637916 @default.
• W3200894866 cites W2062519363 @default.
• W3200894866 cites W2082708772 @default.
• W3200894866 cites W2091616383 @default.
• W3200894866 cites W2105785792 @default.
• W3200894866 cites W2119147717 @default.
• W3200894866 cites W2132554273 @default.
• W3200894866 cites W2149748445 @default.
• W3200894866 cites W2168772082 @default.
• W3200894866 cites W2169178790 @default.
• W3200894866 cites W2170308172 @default.
• W3200894866 cites W2292383635 @default.
• W3200894866 cites W2321871503 @default.
• W3200894866 cites W2412877505 @default.
• W3200894866 cites W2512287004 @default.
• W3200894866 cites W2578082697 @default.
• W3200894866 cites W2578876390 @default.
• W3200894866 cites W2729947947 @default.
• W3200894866 cites W2737651375 @default.
• W3200894866 cites W2755078225 @default.
• W3200894866 cites W2775369717 @default.
• W3200894866 cites W2789120089 @default.
• W3200894866 cites W2809013389 @default.
• W3200894866 cites W2899970113 @default.
• W3200894866 cites W2903062212 @default.
• W3200894866 cites W2903981326 @default.
• W3200894866 cites W2905654445 @default.
• W3200894866 cites W2914550450 @default.
• W3200894866 cites W2970834130 @default.
• W3200894866 cites W2973021197 @default.
• W3200894866 cites W3005184638 @default.
• W3200894866 cites W3082396803 @default.
• W3200894866 cites W3089752214 @default.
• W3200894866 cites W3094426742 @default.
• W3200894866 cites W3110519250 @default.
• W3200894866 cites W3115335364 @default.
• W3200894866 cites W3117034299 @default.
• W3200894866 cites W3119347713 @default.
• W3200894866 cites W3126604828 @default.
• W3200894866 cites W3131612265 @default.
• W3200894866 doi "https://doi.org/10.3389/fonc.2021.726134" @default.
• W3200894866 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8481808" @default.
• W3200894866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34604065" @default.
• W3200894866 hasPublicationYear "2021" @default.
• W3200894866 type Work @default.
• W3200894866 sameAs 3200894866 @default.
• W3200894866 citedByCount "9" @default.
• W3200894866 countsByYear W32008948662021 @default.
• W3200894866 countsByYear W32008948662022 @default.
• W3200894866 countsByYear W32008948662023 @default.
• W3200894866 crossrefType "journal-article" @default.
• W3200894866 hasAuthorship W3200894866A5023940382 @default.
• W3200894866 hasAuthorship W3200894866A5049385418 @default.
• W3200894866 hasAuthorship W3200894866A5053780153 @default.
• W3200894866 hasAuthorship W3200894866A5061270653 @default.
• W3200894866 hasAuthorship W3200894866A5061406271 @default.
• W3200894866 hasAuthorship W3200894866A5070406189 @default.
• W3200894866 hasAuthorship W3200894866A5089086011 @default.
• W3200894866 hasBestOaLocation W32008948661 @default.
• W3200894866 hasConcept C10882517 @default.
• W3200894866 hasConcept C126322002 @default.
• W3200894866 hasConcept C143998085 @default.
• W3200894866 hasConcept C1491633281 @default.
• W3200894866 hasConcept C203014093 @default.
• W3200894866 hasConcept C2776090121 @default.
• W3200894866 hasConcept C2776694085 @default.
• W3200894866 hasConcept C2776999253 @default.
• W3200894866 hasConcept C2778020697 @default.
• W3200894866 hasConcept C2778957590 @default.
• W3200894866 hasConcept C2779338263 @default.
• W3200894866 hasConcept C2780775027 @default.
• W3200894866 hasConcept C2780850621 @default.
• W3200894866 hasConcept C3875195 @default.
• W3200894866 hasConcept C54355233 @default.
• W3200894866 hasConcept C71924100 @default.
• W3200894866 hasConcept C86803240 @default.
• W3200894866 hasConcept C8891405 @default.
• W3200894866 hasConceptScore W3200894866C10882517 @default.
• W3200894866 hasConceptScore W3200894866C126322002 @default.
• W3200894866 hasConceptScore W3200894866C143998085 @default.
• W3200894866 hasConceptScore W3200894866C1491633281 @default.
• W3200894866 hasConceptScore W3200894866C203014093 @default.
• W3200894866 hasConceptScore W3200894866C2776090121 @default.
• W3200894866 hasConceptScore W3200894866C2776694085 @default.

• next